Anti-Human CD20 (Rituximab) [Clone 10F381] – DyLight® 488
Anti-Human CD20 (Rituximab) [Clone 10F381] – DyLight® 488
Product No.: LT911
Product No.LT911 Clone 10F381 Target CD20 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names B1; S7; Bp35; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1 Isotype Human IgG1κ Applications FC |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Rhesus Monkey ⋅ Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human lymphoblastoid cell line SB. Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) RRIDAB_2894036 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only. Background CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects. Antigen Distribution CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Rituximab biosimilars are used in PK bridging ELISA assays as calibration standards or reference controls to establish a standard curve for quantifying drug concentration in serum samples. The biosimilar, which closely mimics originator Rituximab, is prepared at known concentrations and included alongside patient samples during the assay, allowing accurate measurement of Rituximab levels regardless of the specific product in use. Key details on their use in PK bridging ELISA:
In summary, research-grade Rituximab biosimilars serve as quantitative calibrators within PK bridging ELISA, supporting accurate, reproducible measurement of Rituximab concentration in serum across both biosimilar and originator dosing regimens. Standard Flow Cytometry Protocols for Conjugated Rituximab BiosimilarsFlow cytometry is a cornerstone technique for validating both the expression of CD20 on cells and the binding capacity of conjugated Rituximab biosimilars (PE or APC-labeled). Below is a summary of typical protocols and considerations based on established research practices. Sample Preparation
Protocol Steps
Key Assay Controls
Applications and Validation
Example Protocol Summary Table
References to Published Methods
SummaryThe standard protocol involves direct staining of cells with a conjugated Rituximab biosimilar (PE or APC), followed by flow cytometry to quantify CD20 expression and assess binding capacity. Controls are essential for specificity, and functional assays can be integrated for comprehensive validation. These protocols are robust, widely used in both research and quality control, and are supported by peer-reviewed publications and commercial protocol guides. Biopharma companies typically perform a comprehensive suite of analytical assays to confirm both structural and functional similarity between a proposed biosimilar and its originator (reference) biologic. These assays are required to meet stringent regulatory standards and ensure that there are no clinically meaningful differences between the two products. Essential analytical assays fall into the following categories: 1. Structural Characterization:
2. Functional (Biological) Assays:
Key Approaches and Regulatory Context:
Use of Leinco Biosimilar in Analytical Studies: The search results do not provide specific details on the use of Leinco biosimilars in these assays or studies. Leinco Technologies is known as a supplier of antibodies and biosimilars; typically, their biosimilar products would be used by analytical labs and biopharma companies either as:
In these roles, a Leinco biosimilar would serve as either the proposed biosimilar or occasionally as a standard for benchmarking comparative assay results, such as binding, potency, or structural assays. However, without more explicit references in the provided search results, this usage description is based on general industry practice and should be verified via Leinco documentation or peer-reviewed studies for specific examples. In summary, biosimilar comparability is established using a battery of sensitive, orthogonal assays covering both structural and functional attributes, guided by regulatory standards. The Leinco biosimilar, when used, typically serves as a test or reference material in these analytical studies, although specific case details are not provided in the current search results. References & Citations1. Mato, A. et al. (2018) Oncologist. 23(3):288-296. 2. Richards, K. et al. (2018) Front Oncol. 8: 163. Technical ProtocolsCertificate of Analysis |
Formats Available
